Claims
- 1. A method for the treatment of depressive disorders related to neuronal uptake of 5-hydroxytryptamine, the method comprising administration to a host in need of such treatment of a therapeutically effective amount of a compound of the formula ##STR12## or pharmaceutically acceptable acid addition salt thereof, in which formula the groups R.sup.0 are the same or different and are selected from the group consisting of hydrogen, halogen and methyl and the groups R.sup.3 and R.sup.4 are hydrogen.
- 2. A method according to claim 1, wherein the compound of the formula I is ##STR13## or a pharmaceutically acceptable acid addition salt thereof.
- 3. A method according to claim 1, wherein the compound of the formula I is ##STR14## or a pharmaceutically acceptable acid addition salt thereof.
- 4. A method according to claim 1, wherein the compound of the formula I is ##STR15## or a pharmaceutically acceptable acid addition salt thereof.
- 5. A method according to claim 1, wherein the compound of the formula I is ##STR16## or a pharmaceutically acceptable acid addition salt thereof.
- 6. A method according to claim 1, wherein the compound of the formula I is ##STR17## or a pharmaceutically acceptable acid addition salt thereof.
- 7. A pharmaceutical composition for treatment of depressive disorders related to neuronal uptake of 5-hydroxytryptamine, and for oral administration, comprising as active ingredient between 0.2 and 50% by weight of the composition of a compound of the formula ##STR18## or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier in which formula the groups R.sup.0 are the same or different and are selected from the group consisting of hydrogen, halogen and methyl and the groups R.sup.3 and R.sup.4 are hydrogen.
- 8. A pharmaceutical composition for treatment of depressive disorders related to neuronal uptake of 5-hydroxytryptamine, and for injection, comprising as active ingredient between 0.5 and 20% by weight of the composition of a compound of the formula, ##STR19## or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier, in which formula the groups R.sup.0 are the same or different and are selected from the group consisting of hydrogen, halogen and methyl and the groups R.sup.3 and R.sup.4 are hydrogen.
- 9. A pharmaceutical composition according to claim 7, comprising as an active ingredient, a compound of the formula ##STR20## or a pharmaceutically acceptable acid addition salt thereof.
- 10. A pharmaceutical composition according to claim 8 comprising as an active ingredient a compound of the formula ##STR21## or a pharmaceutically acceptable acid addition salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
7403176 |
Mar 1974 |
SEX |
|
Parent Case Info
This application is a division of our application Ser. No. 932,669 of Aug. 8, 1978, now U.S. Pat. No. 4,237,311, which, in turn, was a continuation of our application Ser. No. 757,484 of Jan. 6, 1977 (now abandoned), which, in turn, was a continuation-in-part of our application Ser. No. 554,497 of Mar. 3, 1975 (not abandoned).
Divisions (1)
|
Number |
Date |
Country |
Parent |
932669 |
Aug 1978 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
757484 |
Jan 1977 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
554497 |
Mar 1975 |
|